[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 578,145
  • Shares Outstanding, K 59,115
  • Annual Sales, $ 106,470 K
  • Annual Income, $ 83,230 K
  • EBIT $ 56 M
  • EBITDA $ 115 M
  • 60-Month Beta 0.85
  • Price/Sales 5.40
  • Price/Cash Flow 10.29
  • Price/Book 2.79

Options Overview Details

View History
  • Implied Volatility 99.74% (+9.75%)
  • Historical Volatility 87.87%
  • IV Percentile 51%
  • IV Rank 17.11%
  • IV High 339.85% on 03/03/26
  • IV Low 50.19% on 06/23/26
  • Expected Move (DTE 22) 1.32 (13.70%)
  • Put/Call Vol Ratio 48.42
  • Today's Volume 1,186
  • Volume Avg (30-Day) 1,426
  • Put/Call OI Ratio 1.71
  • Today's Open Interest 50,575
  • Open Int (30-Day) 46,885
  • Expected Range 8.30 to 10.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.08
  • Number of Estimates 3
  • High Estimate $0.10
  • Low Estimate $0.06
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +233.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.10 +5.60%
on 07/24/26
15.03 -36.08%
on 07/08/26
-4.73 (-32.98%)
since 06/30/26
3-Month
9.10 +5.60%
on 07/24/26
15.03 -36.08%
on 07/08/26
-0.56 (-5.51%)
since 04/30/26
52-Week
7.16 +34.22%
on 09/17/25
15.03 -36.08%
on 07/08/26
-1.38 (-12.56%)
since 07/30/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised...

ZVRA : 9.57 (-2.15%)
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

Zevra shares were falling nearly 24% after the Company informed shareholders of the negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ...

ZVRA : 9.57 (-2.15%)
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra”...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potential...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 9.57 (-2.15%)
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

MIPLYFFA  patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June...

ZVRA : 9.57 (-2.15%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 9.57 (-2.15%)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 10.34
2nd Resistance Point 10.09
1st Resistance Point 9.94
Last Price 9.57
1st Support Level 9.53
2nd Support Level 9.28
3rd Support Level 9.13

See More

52-Week High 15.03
Fibonacci 61.8% 12.03
Fibonacci 50% 11.10
Fibonacci 38.2% 10.17
Last Price 9.57
52-Week Low 7.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.